Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 4/20 | 0.38 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 6/20 | 0.36 |
| ▸ | TET3 | O43151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.34 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.34 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 7/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19909714 | 0.83 | CHRM1 (0.42) | BTKJAK3 | |
| SCHEMBL22704583 | 0.83 | CHRM1 (0.42) | BTKJAK3 | |
| SCHEMBL22970007 | 0.83 | CHRM1 (0.42) | BTKJAK3 | |
| SCHEMBL463245 | 0.80 | ALDH1A1 (0.48) | TEAD1TEAD3TET3KMT2AFBXL19 | |
| SCHEMBL25200465 | 0.78 | ALDH1A1 (0.43) | TEAD1TEAD3KMT2A | |
| SCHEMBL22296232 | 0.78 | ALDH1A1 (0.43) | TEAD1TEAD3KMT2A | |
| SCHEMBL17099705 | 0.76 | TEAD1 (0.44) | TEAD1TEAD3BTKTET3KMT2A | |
| SCHEMBL237862 | 0.74 | — | — | |
| SCHEMBL12764449 | 0.74 | TET3 (0.47) | TEAD1TEAD3TET3KMT2AFBXL19 | |
| SCHEMBL167151 | 0.74 | TET3 (0.47) | TEAD1TEAD3TET3KMT2AFBXL19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |